Iloprost (Ventavis, BAYQ6256) ( DrugBank: Iloprost )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03293407 (ClinicalTrials.gov)	February 1, 2018	20/9/2017	Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension	Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension	Hypertension, Pulmonary	Drug: Iloprost (Ventavis, BAYQ6256);Device: Breelib nebulizer	Bayer	NULL	Completed	18 Years	N/A	All	31		Germany
2	NCT01355380 (ClinicalTrials.gov)	August 5, 2010	17/5/2011	Efficacy of Ventavis Used in Real-life Setting.	The Efficacy of Inhaled Iloprost in Patients Treated Within the Pulmonary Arterial Hypertension Therapeutic Programme.	Pulmonary Arterial Hypertension	Drug: Inhaled iloprost (Ventavis, BAYQ6256)	Bayer	NULL	Completed	18 Years	N/A	All	55	N/A	Poland